ЗНАЧЕНИЕ НЕКОТОРЫХ ГЕНЕТИЧЕСКИХ ФАКТОРОВ ДЛЯ ПРОГНОЗА ЭФФЕКТИВНОСТИ ПРОТИВОВИРУСНОГО ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
https://doi.org/10.22625/2072-6732-2014-6-2-48-54
Аннотация
Ключевые слова
полиморфизм гена ИЛ-28B,
РНКа- за L,
HLA-DRB1*11,
HLA-DQB1*03,
хронический гепатит С,
интерферонотерапия
Об авторе
В. М. Мицура
Гомельский государственный медицинский университет, Гомель, Беларусь
Россия
Россия
доцент кафедры инфекционных болезней Гомельского государственного медицинского университета, к.м.н., доцент; тел.: (+375 232)516728
Список литературы
1. Ghany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct; 54(4): 1433– 1444.
2. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Aug;361:580-93.
3. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011 Aug; 55(2): 245-64.
4. Rau M, Baur K, Geier A. Host Genetic Variants in the Pathogenesis of Hepatitis C. Viruses. 2012 Dec; 4(12): 3281-3302.
5. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol. 2011 Jan; 106(1): 38–45.
6. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology. 2011 Jan; 53(1): 336-45.
7. Rauch A, Kutalik Z, Descombes P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology. 2010 Apr; 138(4): 1338-45, 1345.e1-7.
8. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep; 461(7262): 399-401.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 Oct; 41(10): 1105-9.
10. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin- 28B polymorphism improves viral kinetics and s the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul; 139(1): 120-9. e18.
11. Grebely J, Petoumenos K, Hellard M, et al. Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010 Oct; 52(4): 1216-24.
12. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 Oct; 461(7265): 798-801.
13. Lin C-Y, Chen J-Y, Lin T-N, et al. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection PLoS One. 2011; 6(3): e18322.
14. Slev P. Host genomics and HCV personalized medicine. Ann Clin Lab Sci. 2012 Fall; 42(4): 363-9.
15. Bisbal C, Silverman RH. Diverse functions of RNase L and implications in pathology. Biochimie 2007; 89(6-7): 789 – 798.
16. Silverman RH. Viral encounters with 2’,5’-oligoadenylate synthetase and RNase L during the interferon antiviral response J. Virol. 2007; 81(23): 12720 – 12729.
17. Mihm U, Ackermann O, Welsch C, et al. Clinical relevance of the 2–5 -oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis. J Hepatol. 2009 Jan; 50(1): 49-58.
18. Washenberger CL, Han JQ, Kechris KJ, et al. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res. 2007 Dec; 130(1-2): 85-95.
19. Dai C.Y. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res. 2010 Feb; 85(2): 396-402.
20. Marangon AV, Moliterno RA, Sell AM, et al. Influence of HLA alleles in response to treatment with pegylated interferonalpha and ribavirin in patients with chronic hepatitis C. Int J Immunogenet. 2012 Aug; 39(4): 296-302.
21. Ali L, Mansoor A, Ahmad N, et al. Patient HLA-DRB1*and DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol. 2010 Aug; 91(Pt 8): 1931-8.
22. de Rueda PM, López-Nevot MÁ, Sáenz-López P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol. 2011 Jul; 106(7): 1246-54.
23. Sim H, Wojcik J, Margulies M, et al. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat. 1998 Jul; 5(4): 249-53.
24. Mitsura VM, Voropaev EV, Osipkina OV, et al. Laboratornaya diagnostika. Vostochnaya Evropa. 2012; 2: 86–97 (in Russian).
25. Neukam K, Nattermann J, Rallón N, et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin- 28B genotype. HIV Med. 2011 Sep; 12(8): 487-93.
Рецензия
Для цитирования:
Мицура В.М. ЗНАЧЕНИЕ НЕКОТОРЫХ ГЕНЕТИЧЕСКИХ ФАКТОРОВ ДЛЯ ПРОГНОЗА ЭФФЕКТИВНОСТИ ПРОТИВОВИРУСНОГО ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С. Журнал инфектологии. 2014;6(2):48-54. https://doi.org/10.22625/2072-6732-2014-6-2-48-54
For citation:
Mitsura V.M. The value of some genetic factors for prediction of chronic hepatitis C antiviral treatment effectiveness. Journal Infectology. 2014;6(2):48-54. (In Russ.) https://doi.org/10.22625/2072-6732-2014-6-2-48-54
Просмотров: 556
.png)
.png)
Послать статью по эл. почте 